Bright Minds Biosciences (DRUG) vs Faeth Therapeutics (FTH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Faeth Therapeutics (FTH) has outperformed Bright Minds Biosciences (DRUG) over the past year, losing 9.6% versus a loss of 65.2%. Over five years, DRUG leads with a -7.3% price change compared with -95.0% for FTH. Faeth Therapeutics is the larger company by market cap ($203.7 million vs $201.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRUG | FTH |
|---|---|---|
| Share price | $20.40 | $7.88 |
| Market cap | $201.23M | $203.65M |
| 1-day change | -1.45% | -9.32% |
| YTD return | -73.86% | -26.15% |
| 1-year return | -65.18% | -9.64% |
| 5-year return | -7.27% | -94.96% |
| EPS (TTM) | $-2.05 | $-22.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-21.09M |
| 52-week high | $123.75 | $42.14 |
| 52-week low | $17.40 | $7.45 |
| Distance from 52-week high | -83.52% | -81.30% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +426.18% | +612.56% |
| Average volume | 173.24K | 500.25K |
| Shares outstanding | 9.86M | 25.84M |
| Employees | 26 | 29 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- FTH has outperformed DRUG by 55.5 percentage points over the past year.
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
About Faeth Therapeutics
FTH stock →Faeth Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
DRUG vs FTH FAQ
Which is bigger, Bright Minds Biosciences or Faeth Therapeutics?
Faeth Therapeutics (FTH) is larger, with a market capitalization of $203.65M compared with $201.23M for Bright Minds Biosciences (DRUG).
Which stock has performed better over the past year, DRUG or FTH?
FTH returned -9.64% over the past 12 months, compared with -65.18% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are Bright Minds Biosciences and Faeth Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.